 AstraZeneca PLC LSE:AZN said its long-acting antibody combination Evusheld tixagevimab and cilgavimab, formerly AZD7442 has been approved in the EU for the treatment of Covid-19. The approval by the European Commission covers people over the age of 12 years who do not require supplemental oxygen and who are at increased risk of progressing to severe Covid19, the pharmaceuticals group said in a statement. 